Younossi et al., 2014 - Google Patents
The impact of hepatitis C burden: an evidence‐based approachYounossi et al., 2014
View PDF- Document ID
- 11647159381584323144
- Author
- Younossi Z
- Kanwal F
- Saab S
- Brown K
- El‐Serag H
- Kim W
- Ahmed A
- Kugelmas M
- Gordon S
- Publication year
- Publication venue
- Alimentary pharmacology & therapeutics
External Links
Snippet
Background Infection with the hepatitis C virus (HCV) has been considered a major cause of mortality, morbidity and resource utilisation in the US. In addition, HCV is the main cause of hepatocellular cancer (HCC) in the US. Recent developments in the diagnosis and …
- 208000005176 Hepatitis C 0 title description 14
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
- G06F19/345—Medical expert systems, neural networks or other automated diagnosis
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
- G06F19/322—Management of patient personal data, e.g. patient records, conversion of records or privacy aspects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay for hepatitis non-A, non-B hepatitis
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Younossi et al. | The impact of hepatitis C burden: an evidence‐based approach | |
Bartlett et al. | The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: impact of direct acting antivirals | |
Stepanova et al. | Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity | |
Deleuran et al. | Cirrhosis and mortality risks of biopsy‐verified alcoholic pure steatosis and steatohepatitis: a nationwide registry‐based study | |
Armstrong et al. | The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | |
Eslam et al. | Meta‐analysis: insulin resistance and sustained virological response in hepatitis C | |
Younossi et al. | Associations of chronic hepatitis C with metabolic and cardiac outcomes | |
Singal et al. | Alcohol‐associated liver disease in the United States is associated with severe forms of disease among young, females and Hispanics | |
Fabrizi et al. | Post‐transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta‐analysis of clinical studies | |
Teschke et al. | Drug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue? | |
Fu et al. | Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with new onset diabetes: a nationwide cohort study | |
Chen et al. | Meta‐analysis: IL 28 B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon‐α and ribavirin | |
Gordon et al. | Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study | |
Rangnekar et al. | Meta‐analysis: IL‐28 B genotype and sustained viral clearance in HCV genotype 1 patients | |
Rutter et al. | Successful anti‐viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C | |
Brown et al. | Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs | |
Vagu et al. | Serum iron markers in patients with chronic hepatitis C infection | |
Ko et al. | Diabetes, hepatitis virus infection and hepatocellular carcinoma: a case–control study in hepatitis endemic area | |
Kallman et al. | Screening for hepatitis B, C and non‐alcoholic fatty liver disease: a survey of community‐based physicians | |
Van Der Meer et al. | Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters | |
Huang et al. | Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: a nation‐wide cohort study | |
Trimble et al. | Mortality associated with alcohol‐related liver disease | |
Kim et al. | Insulin resistance and the risk of hepatocellular carcinoma in chronic hepatitis B patients | |
Younossi et al. | Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C | |
Huang et al. | Diabetes, hepatocellular carcinoma, and mortality in hepatitis C‐infected patients: a population‐based cohort study |